1Roglic G,Unwin N,Bennett PH. The burden of mortality attributable to diabetes:realistic estimates for the year 2000[J].{H}DIABETES CARE,2005,(09):2130-2135.
2Rastogi A,Walia R,Dutta P. Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma:a prospective randomized trial[J].Indian J Endocrinol Metab,2012,(Suppl 2):294-296.
3Nak D,Nak Y,Simsek G. Comparison of the use of cabergoline and gonadotrophin to treat primary and secondary anoestrus in bitches[J].{H}Australian Veterinary Journal,2012,(05):194-196.
4Ratner LD,Gonzalez B,Ahtiainen P. Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility[J].{H}ENDOCRINOLOGY,2012,(12):5980-5992.
5Dosa PI,Ward T,Walters MA. Synthesis of novel analogs of cabergoline:improving cardiovascular safety by removing 5-HT2B receptor agonism[J].ACS Med Chem Lett,2013,(02):254-258.
6Seow KM,Lin YH,Bai CH. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS:a randomized controlled trial[J].{H}Reproductive BioMedicine Online,2013,(06):562-568.
7Garber AJ,Blonde L,Bloomgarden ZT. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations[J].{H}Endocrine Practice,2013,(01):100-106.
8Ciresi A,Amato MC,Guarnotta V. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels[J].{H}Clinical Endocrinology(Oxford),2013.
